28 related articles for article (PubMed ID: 30172381)
1. Chalazion in a patient with multiple myeloma treated with bortezomib.
Ghimire B; Hamajima Y; Carbajal-Carballo L; Anusim N
BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36593601
[TBL] [Abstract][Full Text] [Related]
2. Chalazia associated with bortezomib therapy for multiple myeloma.
Grob SR; Jakobiec FA; Rashid A; Yoon MK
Ophthalmology; 2014 Sep; 121(9):1845-7.e3. PubMed ID: 24974380
[No Abstract] [Full Text] [Related]
3. Association Between Bortezomib Therapy and Eyelid Chalazia.
Fraunfelder FW; Yang HK
JAMA Ophthalmol; 2016 Jan; 134(1):88-90. PubMed ID: 26469392
[TBL] [Abstract][Full Text] [Related]
4. Management and outcomes of proteasome inhibitor associated chalazia and blepharitis: a case series.
Sklar BA; Gervasio KA; Leng S; Ghosh A; Chari A; Wu AY
BMC Ophthalmol; 2019 May; 19(1):110. PubMed ID: 31088416
[TBL] [Abstract][Full Text] [Related]
5. Marking technique to improve primary success of incision and curettage of eyelid chalazia.
Varma S; Kam JK
Clin Exp Ophthalmol; 2018 Jan; 46(1):89-90. PubMed ID: 28548678
[No Abstract] [Full Text] [Related]
6. Bortezomib ocular toxicities: Outcomes with ketotifen.
Dennis M; Maoz A; Hughes D; Sanchorawala V; Sloan JM; Sarosiek S
Am J Hematol; 2019 Mar; 94(3):E80-E82. PubMed ID: 30575098
[No Abstract] [Full Text] [Related]
7. Chalazia associated with bortezomib therapy.
Laaribi N; Abdellaoui T; Abaloun Y; Fiqhi A; Rabii H; Haidouri S; Mouzari Y; El Asri F; Reda K; Oubaaz A
J Fr Ophtalmol; 2018 Oct; 41(8):e381-e382. PubMed ID: 30172381
[No Abstract] [Full Text] [Related]
8. Optimizing therapy in bortezomib-exposed patients with multiple myeloma.
Migkou M; Gavriatopoulou M; Terpos E; Dimopoulos MA
Expert Rev Hematol; 2018 Jun; 11(6):463-469. PubMed ID: 29788798
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: a meta-analysis.
Sun CY; Li JY; Chu ZB; Zhang L; Chen L; Hu Y
Biosci Rep; 2017 Aug; 37(4):. PubMed ID: 28706008
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: An overview of systematic reviews with meta-analyses.
Aguiar PM; de Mendonça Lima T; Colleoni GWB; Storpirtis S
Crit Rev Oncol Hematol; 2017 May; 113():195-212. PubMed ID: 28427509
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib-induced syndrome of inappropriate antidiuresis in a patient with multiple myeloma: A case report and literature review
.
Peng B; Chen H; Lou X
Int J Clin Pharmacol Ther; 2017 Dec; 55(12):910-914. PubMed ID: 29092733
[TBL] [Abstract][Full Text] [Related]
12. [MAS-like lesions and SIADH caused by bortezomib in the treatment of multiple myeloma : three cases report and literature review].
Wang LL; Geng CY; Zhang YR; Wu Y
Zhonghua Xue Ye Xue Za Zhi; 2022 Jan; 43(1):75-77. PubMed ID: 35231998
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
